AstraZeneca wins first US trial over Seroquel diabetes claims
This article was originally published in Scrip
Executive Summary
A US jury has ruled in favour of AstraZeneca with regard to the mass tort litigation for Seroquel (quetiapine fumarate), handing down the first verdict in a trial over claims that the product caused diabetes and that the risks were not properly conveyed to patients and physicians. It is the first verdict to come out of more than 10,000 US plaintiffs suing the company over Seroquel diabetes claims.